In the U.S., by contrast, rapid tests are hard to find, because the Food and Drug Administration has been slow to approve them. F.D.A. officials have defended their reluctance by saying that they need to make sure the tests work — which they certainly do. But many outside scientists have criticized the agency for blocking even those antigen tests with a demonstrated record of success in other countries.
The F.D.A. has preferred a different kind of test, known as a P.C.R. test, which is sensitive enough to identify many noninfectious cases (including some that are weeks old). But P.C.R. tests come with a crucial downside: Many must be processed in a laboratory and take more than 24 hours to return results. In the meantime, a person with Covid may spread it to others.
Fortunately, though, today’s newsletter is not just another recounting of this country’s testing shortcomings. There has been some news this week. Soon, Americans will probably have better access to rapid tests than they now do.
More tests, soon
The F.D.A. announced Monday that it would allow the sale of an antigen test known as Flowflex. The test has been available in Europe but not here, even though the company that makes it — Acon Laboratories — is based in San Diego.
The decision suggests that the F.D.A. has become willing to approve other rapid tests too, Alex Tabarrok, an economist at George Mason University and an advocate of expanded testing, told me. Separately, the Biden administration plans to announce an expansion of rapid testing today, a White House official told me last night. It will be a $1 billion government purchase of tests, meant to accelerate their production, on top of other money the administration has already dedicated to rapid tests.